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Abstract Ras signaling pathways play an important role
in cellular proliferation and survival, and inappropriate
activation of Ras frequently results in cell transformation
and cancer. Human T-cell leukemia/lymphoma virus type 1
(HTLV-1) is the etiological agent of the adult T-cell leu-
kemia/lymphoma (ATLL), a severe malignancy that has a
poor prognosis and exhibits resistance to conventional
chemotherapy. Although the mechanisms involved in cell
transformation by HTLV-1 have not been completely
clariﬁed, it is generally thought that Tax plays a pivotal
role in the process. We have previously proposed that a
functionally active Ras protein is needed for efﬁcient anti-
apoptotic activity of Tax. In this study we report data
indicating that the apoptotic resistance of cells expressing
Tax, constitutively or transiently, is linked to the intracel-
lular levels of Ras-GTP. Indeed, we found that Tax-posi-
tive cells have a high content of active Ras, and that
inhibition of Ras signaling, using the antagonist farnesyl
thyosalicylic acid (FTS), increases their sensitivity to
apoptosis. FTS treatment was also accompanied by a
decrease in ERK, but not Akt, phosphorylation. Thus, all
together our data suggest that the interaction between Tax
and Ras could be important to ATLL pathogenesis, and
indicate Ras as a possible target for therapeutic interven-
tion in ATLL patients.
Keywords HTLV-1  Tax  Ras  Apoptosis  ERK1/2 
Akt
Introduction
Ras proteins are small GTPases that function as molecular
switches, alternating between inactive (GDP-bound) and
active (GTP-bound) states. Like many genes involved in
the regulation of multiple cellular signaling pathways (i.e.,
differentiation, proliferation and survival), Ras when
aberrantly expressed, contributes to cancer development
[1–4]. We have previously described a possible link
between Ras signaling and resistance to apoptosis of cells
expressing the Tax protein of Human T-cell leukemia virus
type 1 (HTLV-1) [5].
HumanT-cellleukemiavirustype1isthecausativeagent
of adult T-cell leukemia/lymphoma (ATLL) [6, 7] and
HTLV-1 associated myelopathy/tropical spastic paraparesis
(HAM/TSP) [8]. Even though the mechanisms by which the
virus engenders disease are not yet completely understood,
numerous evidences indicate the multifunctional Tax pro-
tein as essential for malignant transformation (reviewed in
[9]). Indeed, Tax causes leukemia in transgenic mice [10],
and immortalizes human lymphocytes when expressed in
either a herpes- or retroviral vector [11, 12]. This oncogenic
potential is accounted for by Tax ability to modulate the
synthesis or the activity of many cellular proteins that con-
trol a variety of fundamental cellular processes [13].
A key feature of malignant transformation is the
induction of apoptotic resistance [14], and aberrant cell
death is usually associated with uncontrolled cell growth.
Tax contribution to apoptosis is still controversial since the
protein was shown to possess both anti-apoptotic and pro-
apoptotic activity [15–17]. However, at present, it is gen-
erally accepted that the anti-apoptotic activity of Tax
overrides its potential pro-apoptotic effects.
In previous studies, using murine ﬁbroblasts and human
HeLa cells, we have shown that Tax expression induces
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Analysis of potential mechanisms revealed that the
observed resistance was linked to high levels of trans-
criptionally active CREB and to the presence of a func-
tional Ras protein [5, 18, 19].
In this study, carried out on human T-cells, we report
data indicating that Tax-expressing cells have high levels
of Ras-GTP (active form), and we demonstrate that Ras-
GTP contributes to Tax-mediated apoptosis protection.
Indeed, treatment of cells with a Ras antagonist decreased
their apoptotic resistance; treatment was also accompanied
by a reduction of both Ras-GTP and phosphorylated
ERK1/2.
All together, our results suggest an important role for
Ras signaling in Tax-mediated apoptotic resistance and
support the notion that Ras activation might be important
for ATLL development.
Materials and methods
Cell culture and plasmid
Jurkat, and derived clones, Hut-102, JPX9, and Molt3 cell
lines were maintained in RPMI 1640 medium supple-
mented with 10% fetal bovine serum (FBS) and 2 mM
L-glutamine. HeLa-tat cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with
10% FBS and 2 mM L-glutamine. Jurkat clones expressing
Tax were obtained by electroporation with the Tax-
expressing plasmid pLcXL [20], together with a plasmid
expressing the neomycin-resistance gene (p-exo-neo).
Following selection with G418, the resulting clones were
expanded and characterized. In parallel, Jurkat cells were
also electroporated with the p-exo-neo vector alone to
generate control clones. Fugene 6 (Roche Diagnostics,
Mannheim, Germany) was used to transiently transfect
HeLa-tat cells with a plasmid expressing Tax under the
control of the cytomegalovirus promoter (pCMV-Tax)
[21]. Expression of Tax in JPX9 cells was induced by
addition of CdCl2 to a ﬁnal concentration of 10 lM.
Western blot assay and Ras-GTP selective precipitation
Total proteins were extracted directly in Laemmli buffer; a
cocktail of protease inhibitors (Roche) was included in
every extraction. Equal volumes of cell lysates, corre-
sponding to 4 9 10
5 Jurkat cells or 5 9 10
4 HeLa cells (or
30 lg of proteins quantiﬁed using the Coomassie Plus
Reagent kit, Thermo Scientiﬁc) were separated by SDS-
PAGE electrophoresis in 10% or 15% gels and then trans-
ferred to PVDF membranes (Amersham GE Healthcare,
UK). Cytosolic fractions were prepared by selective plasma
membrane permeabilization with 0.05% digitonin in an
isotonic sucrose buffer, as previously described [19]. Ras-
GTP was identiﬁed by precipitation with Gst-tagged Raf1-
RBD (Ras Activation Assay Kit; Cytoskeleton Inc., Denver,
CO, USA) followed by immunoblotting. The following
antibodies were used: rabbit anti-Tax serum obtained from
the AIDS Research Reagents Collection [22], mouse
monoclonal anti-pan-Ras (Sigma-Aldrich Inc., St Luis, MO,
USA or Cytoskeleton Inc.), monoclonal antibody 7H8.2C12
against cytochrome c (BD Biosciences, Franklin Lakes, NJ,
USA), goat anti-Hsp60 polyclonal antibody N-20 (Santa
Cruz Biotechnology), mouse monoclonal anti-tubulin
(Sigma-Aldrich Inc.), rabbit polyclonal anti-PARP, rabbit
polyclonal anti-cleaved caspase 3, mouse monoclonal anti-
phosphorylated Ser-473 Akt, rabbit polyclonal anti-total
Akt, rabbit polyclonal anti-total ERK1/2, and mouse
monoclonal anti-phosphorylared ERK1/2, all from Cell
Signaling Technology (Danvers, MA, USA).
Annexin V cell death assay
Jurkat and JD1 cells (2 9 10
5/ml) were treated for 24 h
with 10 lM cisplatin. The Annexin V assay was performed
using an Annexin V-FITC (Roche), according to manu-
facturer’s instructions. In brief, 5 9 10
5 cells were col-
lected, centrifuged, rinsed with Annexin-binding buffer
(RPMI containing 10 mM HEPES and 0.1% bovine serum
albumine (BSA)) and then incubated in 500 ll of RPMI/
HEPES/BSA buffer containing 1 lg/ml propidium iodide
and 10 ll/ml Annexin V-FITC for 10 min at room tem-
perature. The samples were analyzed by ﬂow cytometry
using a Coulter Epicsxl, with 10,000 ungated events
examined for each sample.
Confocal microscopy analysis
HeLa-tat cells were seeded on glass coverslips in 35 mm
tissue culture plates at a concentration of 2 9 10
5 cells.
Twenty-four hours after transfection, cells were treated
with 60 lM cisplatin for 4–6 h and than ﬁxed for 30 min in
4% formaldehyde, permeabilized for 2 min with 0.2%
Triton X-100/PBS and immunodecorated. The murine anti-
cytochrome c monoclonal antibody 6H2.B4 (BD Biosci-
ences) and the rabbit anti-Tax serum (see above) were used
as primary antibodies. Alexa 488- and Alexa 546-conju-
gated secondary antibodies were purchased from Molecular
Probes. Coverslips were analyzed using a Zeiss LSM510
confocal laser microscope.
Chloramphenicol acetyl transferase (CAT) assay
Parental Jurkat cells and derived clones were transiently
transfected by the DEAE–Dextran method [23] with the
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with a CMV-b-gal plasmid. Twenty-four hours later the
cells were collected, rinsed with PBS and lysed by three
freeze–thaw cycles in 50 ll of 0.25 M Tris–HCl pH7.8.
Aliquots of the supernatants were assayed for CAT activity
as previously described [24]; the percentage of chloram-
phenicol conversion to its acetylated forms was determined
using an InstantImmager (Packard Instrument Company,
Meriden, CT, USA), and normalized for b-Gal activity.
Results
Generation and characterization of Tax-expressing
T-cells
To assess the role of Tax protein in the apoptotic behavior
of T-cells, we generated stable Tax-positive T-cells by
transfecting the Jurkat cell line with a plasmid expressing
Tax under the control of the HTLV-1 LTR, together with a
plasmid expressing neomycin-resistance. Transfected cells
were, thus, selected with neomycin and the resulting clones
expanded. Corresponding controls were generated by
transfecting Jurkat cells with mock DNA together with the
selectable plasmid. The stable expression of Tax was ver-
iﬁed by both CAT assay and Western blot. Results showed
that only one of the isolated clones, named JD1, expressed
an active and detectable Tax protein (Fig. 1a, b), suggest-
ing that in the other clones tax was, most likely, lost or
inactivated.
When we tested the resistance of the isolated clones to
cisplatin-induced apoptosis, we found that only JD1 cells
were resistant to death, measured as percentage of PARP
cleavage, after 24 h treatment. In contrast, the parental
Jurkat cells, the mock-transfected clones as well as the
Tax-transfected cells that had lost Tax activity, were sus-
ceptible to cisplatin treatment (Fig. 1c). The resistance of
JD1 cells to apoptosis induced by cisplatin treatment was
also conﬁrmed by Annexin V cell death assay (Fig. 1d).
However, by changing the duration of treatment to 48 h
(Fig. 1e) or the drug dosage (data not shown), it was pos-
sible to increase the percentage of apoptotic JD1 cells.
Similar results were obtained when the cells, after 24 h of
treatment were grown for additional 24 h in drug free
medium. In this experimental setting, both Jurkat and JD1
cells resulted susceptible to drug doses that were ineffec-
tive, or only slightly effective, after 24 h (Fig. 1f). These
results suggested that the apoptotic machinery was still
working in JD1 cells and that their resistance was probably
due to an increased threshold of sensitivity to apoptotic
stimuli. JD1 cells exhibited similar behavior when other
apoptosis inducers, such as etoposide or ceramide, were
used (not shown).
It has been reported that Tax can transactivate the MDR-
1 (multidrug resistance) gene promoter [25] and that ATLL
cells very often show an enhanced MDR-1 expression [26].
Hence, we tested whether the observed increased resistance
of JD1 cells could be ascribable to P-glycoprotein over-
expression. As reported in Fig. 1g, we found that con-
comitant treatment with cisplatin and verapamil, a known
inhibitor of the MDR pump [27], induced an increase in the
death percentage of JD1 cells; however, a similar incre-
ment was also observed in Jurkat cells indicating that JD1
and Jurkat cells have comparable MDR-1 pump activity
and that other mechanisms of resistance should be at work
in JD1 cells (Fig. 1g).
Resistance to apoptosis is not restricted to JD1 cells
To determine whether resistance to apoptosis was restricted
to JD1 cells or was instead a more general phenomenon in
Tax-positive T-cells, we analyzed the response to cisplatin
treatment of Hut-102 and JPX9 cell lines. Hut-102 is an
ATLL derived cell line expressing constitutively a high
amount of Tax [28]. On the contrary, JPX9 is a Tax-
inducible cell line generated by introducing in Jurkat cells
the Tax gene under the control of a metallothionein pro-
moter [29], and expression of Tax is induced by cells
treatment with heavy metals. As reported in Fig. 2a, Hut-
102 cells exhibited a higher resistance to cisplatin-induced
apoptosis than the non-infected MOLT3 T-cells, included
as control. Comparable results were obtained with JPX9
cells, since the induction of Tax expression by CdCl2
treatment was accompanied by a decreased sensitivity to
cisplatin (Fig. 2b).
Tax expression blocks cytochrome c release
from mitochondrial intermembrane compartment
We previously reported that Tax induces resistance to
apoptotic stimuli, such as growth factors withdrawal or Bax
overexpression, by interfering with the mitochondrial
apoptotic pathway [18, 19, 30]. As mitochondria play a
pivotal role in the control of apoptosis triggered by che-
motherapeutic drugs, we investigated whether Tax inter-
feres with cisplatin-induced apoptosis by inhibiting the so
called intrinsic apoptotic pathway. Thus, as a parameter of
mitochondrial engagement, we tested the release of cyto-
chrome c from mitochondria, a key event in the mito-
chondrial apoptotic pathway, after cisplatin treatment. We
found that in a culture of HeLa-tat cells transiently trans-
fected with a Tax-expressing plasmid and then treated with
cisplatin, cytochrome c release was present almost exclu-
sively in the Tax-negative cells (Fig. 3a, b). Similarly, after
extraction with digitonin, that selectively permeabilizes
plasma and outer mitochondrial membranes to derive
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visualized in the cytosolic fraction of JD1 cells (Fig. 3c).
These results indicate that Tax protects T-cells from cis-
platin-induced apoptosis by blocking the mitochondrial
apoptotic pathway. In line with these ﬁndings, no activa-
tion of the caspase 3 was observed in JD1 cells after
treatment with cisplatin (Fig. 3c).
Ras activation is responsible for the apoptotic resistance
of Tax-expressing cells
Wethensoughttoinvestigatethemolecularmechanismsthat
could make Tax-expressing cells more resistant to apoptotic
stimuli thattriggerthe mitochondrialpathway.Our previous
data, in HeLa cell system, suggested the participation of Ras
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123signaling in Tax-mediated protection from apoptosis.
Indeed, we showed that Tax interacts with the GTPase
activating protein GAP
1m. As GAPs favor the hydrolysis of
Ras-GTP (active form) into Ras-GDP (inactive form), our
working model proposed the presence of high levels of
activated Ras in Tax-expressing cells due to a Tax-mediated
inefﬁcient conversion of Ras-GTP into Ras-GDP [5].
Here, to substantiate this hypothesis, we compared the
amount of Ras-GTP present in Tax-positive JD1 cells with
that of parental Jurkat cells and apoptosis-sensitive Jurkat-
derived clones. The analysis was carried out by exploiting
the greater afﬁnity of Raf1-RBD (Ras-binding domain) for
Ras-GTP. Indeed, Raf1-RBD binds very tightly to the
GTP-bound form of Ras, while RBD afﬁnity for Ras-GDP
is three orders of magnitude lower [32]. As reported in
Fig. 4, we found that JD1 cells have levels of Ras-GTP
higher than those found in parental Jurkat cells and in Tax-
negative Jneo3 and Jneo6 clones (Fig. 4a). Interestingly,
the JA1 clone, derived from the same transfection as the
JD1 cells, but that had lost Tax activity (Fig. 1a) and was
cisplatin-susceptible (Fig. 1c), also showed a low level of
Ras-GTP (Fig. 4a). Consistently, an increased amount of
activated Ras was also detected in the Tax-inducible JPX9
cells after treatment with CdCl2 (Fig. 4b) and in Tax-
transfected HeLa-tat cells (Fig. 4c). No induction of Ras
activation was observed in mock-transfected HeLa-tat
cells, and more interestingly in the same cells transfected
with the non-protective Tax-mutant M47 (Fig. 4c).
These ﬁndings strongly indicate that the activation of
Ras signaling could be one of the mechanisms by which
Tax increases resistance to cisplatin-induced cell death.
Ras controls several effector proteins, including PI3K/
Akt and MEK/ERK, that regulate signaling involved in cell
survival and CREB phosphorylation. Akt has been reported
to be activated in HTLV-1 transformed cells or Tax-
expressing cells [33–35] and we showed that the MEK/
ERK pathway is involved in Tax-mediated apoptosis pro-
tection, in HeLa cells [5]. Hence, we compared the phos-
phorylation state of Akt and ERK proteins in JD1 and
parental Jurkat cells. As reported in Fig. 4d, JD1 cells
Fig. 2 Effect of cisplatin treatment in HTLV-1 infected Hut-102 or
Tax-inducible JPX9 cell lines. PARP cleavage after cisplatin
treatment was evaluated by Western blot. Protein aliquots corre-
sponding to 4 9 10
5 of HTLV-1 infected Hut-102 and HTLV-1
negative control MOLT-3 (a) or Tax-inducible JPX9 (b) cells were
separated by SDS-PAGE, transferred to PVDF membranes and then
immunodecorated with anti-PARP or anti-Tax antibodies. To induce
Tax expression, JPX9 cells were grown for 24 h in medium
containing 10 lM CdCl2 before treatment with cisplatin. Histograms
represent percentage of cleaved PARP, resulting from densitometric
analysis
Fig. 1 Phenotypic characterization of Jurkat-derived clones. a Anal-
ysis of Tax activity in Tax-transfected Jurkat derivatives. Cells were
transiently transfected with an LTR-CAT plasmid; the b-galactosidase
expression vector CMV-b-gal was added as a control of transfection
efﬁciency. Percentage of chloramphenicol acetylation was calculated
as described in ‘‘Materials and methods’’ and normalized for b-gal
activity. b Western blot analysis of Tax expression in Jurkat cell
derivatives; tubulin is shown as a loading control. c Western blot
analysis of PARP cleavage after treatment with cisplatin for 24 h.
Aliquots corresponding to 4 9 10
5 cells (or to 30 lg of total proteins)
were subjected to SDS-PAGE, transferred to PVDF membranes and
then immunodecorated with an anti-PARP antibody. d Annexin V cell
death assay in Jurkat and JD1 cells treated with cisplatin for 24 h.
eWesternblotanalysisofPARPcleavageinJurkatandJD1cellstreated
for 48 h with cisplatin. f Western blot analysis of cell death
susceptibility of Jurkat and JD1 cells treated with cisplatin for 24 h
andthengrowthforadditional24 hincisplatin-freemedium.gAnalysis
oftheeffectofcisplatintreatmentinthepresenceoftheMDR1inhibitor
verapamil. Cells were treated with cisplatin for 24 h in the presence of
20 lg/ml verapamil. At the end of treatment proteins were extracted as
described in the ‘‘Materials and methods’’ and analyzed by Western
blot.HistogramsrepresentpercentageofcleavedPARP,resultingfrom
densitometric analysis
b
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ERK than Jurkat cells, likely as a consequence of the
increased amount of activated Ras.
Inhibition of Ras signaling reduces resistance
to apoptosis of Tax-positive cells
To verify whether increased Ras activation is involved in
Tax-mediated apoptotic resistance and enhanced Akt and
ERK phosphorylation, we treated the cells with farnesyl
thyosalicylic acid (FTS). FTS is a Ras farnesylcystein
mimetic, that selectively disrupts the association of active
Ras protein with the plasma membrane and can thus be
considered as a Ras inhibitor [36].
At ﬁrst we evaluated the effect of FTS treatment on Ras-
GTP levels. As reported in Fig. 5a, when JD1 cells were
treated for 24 h with a not toxic dose of FTS (50 lM), we
observed a considerable reduction in the active form of Ras
compared to untreated control cells. Analysis of the
apoptotic behavior of JD1 cells treated with the Ras
inhibitor, indicated that the combined administration of
cisplatin and FTS increased the cytotoxic effects of cis-
platin in JD1 cells (Fig. 5b); similar results were obtained
when different timing of treatment and different doses of
cisplatin were used (Fig. 5c).
Since, as reported in Fig. 4c, JD1 cells have high levels
of activated Akt and ERK proteins, we analyzed these
proteins after FTS treatment. Western blot analysis showed
that while the level of phospho-Akt did not change, the
amount of phospho-ERK decreased considerably after
treatment (Fig. 5d). All together, these results further
support the hypothesis that an active Ras plays a relevant
role on Tax-mediated resistance to apoptosis and implicate
the MAPK/ERK pathway as one of its effectors.
Discussion
Ras family proteins cycle between inactive GDP-bound
and active GTP-bound states and function as molecular
switches for signaling pathways that regulate many aspects
of cell behavior including cell division, differentiation,
transformation and survival [2].
It has also been reported that Ras plays a relevant role in
T-cell maturation and accumulates in the active GTP-
bound form in response to some cytokines or to T-cell
antigen receptor (TCR) stimulation [37]. Deregulated Ras
signaling is present in numerous human cancers, including
Fig. 3 Analysis of cytochrome c distribution in Tax-positive and
Tax-negative cell lines after cisplatin treatment. a Confocal analysis
of HeLa-tat cells transiently transfected with a CMV-Tax plasmid and
then treated with 60 lM cisplatin for 6 h. Arrows indicate cells with
cytochrome c release. Graph represents percentage of Tax-positive
and Tax-negative HeLa-tat cells exhibiting cytochrome c release; data
report mean values ± SE of at least 600 cells randomly counted in
three independent experiments. b Western blot analysis of cyto-
chrome c release in Jurkat and JD1 cells after treatment with 5 lM
cisplatin for 24 h. Digitonin-extracted cytosolic or total protein
fractions were separated by SDS-PAGE and immunodecorated using
antibody speciﬁc for cytochrome c. The hsp60 antibody was used as
control. c Western blot analysis of caspase 3 activation in Jurkat and
JD1 cells after treatment with cisplatin for 24 h; tubulin is shown as a
loading control
b
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123hematopoietic disorders [1, 38–40]. An active Ras might
contribute to both inhibition of apoptosis, and development
of tumor cell resistance to chemotherapy and ionizing
radiation [41, 42]. Deregulated Ras activation is achieved
mainly through mutations [1]; however, malfunction of
GTPase activating proteins (GAPs), that regulate the con-
version of GTP-bound to GDP-bound Ras forms, can also
affect the intracellular level of activated Ras [43].
HTLV-1 is a deltaretrovirus that immortalizes and
transforms human T lymphocytes and is the causative
agent of the ATLL; prognosis for ATLL patients remains
poor because of tumor cells resistance to conventional,
apoptosis-inducing, chemotherapeutic agents. Although
many HTLV-1 basic functions have been clariﬁed, thera-
peutic strategies are still unsuccessful, with few responder
patients and a poor survival [16]. Tax protein, with its
pleiotropic activity, is considered the oncogenic product of
HTLV-1 and the main culprit of cell death resistance in
infected tumor cells.
We previously provided evidence that Tax needs a
functionally active Ras protein for the induction of apop-
totic resistance [5]. Furthermore, we and others have shown
that Tax co-precipitates with the Ras-GAP
1m protein [5,
44]. On the basis of these ﬁndings, we proposed a working
Fig. 4 Tax-expressing cells exhibit high levels of Ras-GTP, and
ERK1/2 and Akt phosphorylation. Lysates from 10 or 5 9 10
6 Tax-
negative (Jurkat, Jneo3, Jneo6 and JA1) or -positive (JD1) cells (a),
and from 5 9 10
6 Tax-inducible JPX9 cells (b), were precipitated
using Gst-tagged Raf1-RBD and subjected to Western blot. Precip-
itated RasGTP and total Ras (input) were detected using a pan-Ras
antibody, as described in ‘‘Materials and methods’’; input represents
1/60 of total lysate used for precipitation. To induce Tax expression,
JPX9 cells were grown 24 h before precipitation in medium
containing 10 lM CdCl2. c Detection of Tax-induced Ras-GTP in
HeLa-tat after transient transfection with plasmids expressing Tax
wild type or its mutant M47. Cells lysate was precipitated with Gst-
tagged Raf1-RBD followed by blotting and immunodecoration with a
pan-Ras antibody. Histograms in a, b, and c represent the ratio
between Ras-GTP and the input, resulting from densitometric
analysis. d Analysis of phosphorylated forms of Akt and ERK in
Jurkat and JD1 cells. Aliquots corresponding to 30 lg of total
proteins were subjected to Western blot and immunodecorated with
antibodies speciﬁc for ERK1/2 and Akt or their phosphorylated
(P) forms
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(i.e., GTP-bound) conformation, due to a defective guanine
nucleotide hydrolysis, as a result of Tax/GAP interaction
[5].
Here, while investigating the molecular mechanisms of
Tax-mediated resistance to apoptosis in T-cells, we found
that cells expressing Tax either transiently or constitutively
have higher levels of Ras-GTP than their control counter-
parts. These data are consistent with the proposed mecha-
nism of action of Tax and strengthen previous ﬁndings
indicating that Tax-mediated resistance to apoptosis is, at
least in part, associated with Ras activity. Indeed, we show
that inhibition of Ras signaling is accompanied by an
increased sensitivity to cisplatin treatment. It was previ-
ously reported that a combined treatment with cisplatin and
inhibitors of Ras farnesylation increases the cytotoxic
effect of the cisplatin alone [45]. In addition, it was also
reported that protein geranylgeranylation is essential for
ATLL cell survival [46]. Instead of farnesylation or gera-
nylgeranylation inhibitors, we used FTS (S-farnesylthio-
salicylic acid), a Ras farnesylcystein mimetic that
selectively interacts with the activated form of Ras. FTS
has a very low toxicity, and has been reported to restrain
the growth of tumor cells in vivo [36, 47, 48]. We found
that treatment of JD1 cells with FTS was accompanied by a
decrease in Ras-GTP and a parallel increase in sensitivity
to cisplatin treatment. Interestingly, increased apoptosis
susceptibility of Tax-expressing cells to treatment with
FTS was accompanied by a consistent reduction in phos-
pho-ERK, suggesting a direct involvement of ERK acti-
vation in the apoptosis protection mediated by Tax.
Moreover, although several reports stressed the potential
relevance of Akt activation in survival of HTLV-1 infected
or Tax-expressing cells, no reduction in phospho-Akt was
observed after FTS treatment. The different behavior of
ERK and Akt could be the result of the diverse activation
pattern of the two proteins. Indeed, ERK activation is
directly linked to Ras through the Raf-MEK pathway,
whereas Akt is a downstream effector of PI3K, whose
activation can be driven not only by Ras but also by diverse
inducers [49–51]. Thus, Ras inhibition has likely a more
direct and rapid effect in ERK activation.
Fig. 5 Treatment with the Ras
inhibitor FTS acid sensitizes
Tax-positive cells to cisplatin-
induced cell death. a Lysates of
JD1 cells treated with FTS
(50 lM) for 24 h were
precipitated using Gst-tagged
Raf1-RBD and immunoblotted.
Ras was detected with a pan-
Ras antibody. Histogram
represents densitometric
analysis of the Ras-GTP/input
ratio. b Cells were treated with
cisplatin and FTS (50 lM) for
24 h and then processed for
PARP analysis. Histograms
represent ratio between cleaved
and uncleaved PARP forms,
resulting from densitometric
analysis. c FTS (50 lM) and
cisplatin were added at the same
time. After 24 h the culture
medium was changed and cells
were post incubated in cisplatin-
free medium with or without
FTS (50 lM). Actin was
included as loading control.
Histograms represent ratio
between cleaved and uncleaved
PARP forms obtained by
densitometric analysis. d Effect
of FTS on the phosphorylated
form of Akt and ERK in JD1
cells. Total proteins and
phosphorylated (P) forms were
detected as in Fig. 4
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123Recently, it has been shown that one other protein of
HTLV-1, the p13, can act in a opposite manner to Tax
favoring cell death by interfering with the Ras pathway
[52]; furthermore it has also been reported that nuclear p13
binds Tax and inhibits its transcriptional activity [53].
Thus, analysis of Ras role in lymphocytes expressing the
entire HTLV-1 genome will be of great interest.
Nonetheless, our data provide evidence of Ras signaling
activation in Tax-expressing T-cells, and indicate this
occurrence as a possible cause of ATLL cell resistance to
death by chemotherapeutic agents. Although additional
studies should evaluate whether the levels of Ras-GTP
correlate with disease prognosis and the extent of apoptosis
resistance, our data indicate in Ras a possible target for
ATLL therapy.
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